trial

A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

NCTId NCT05359081
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 68 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2024-03-21
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
68 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2022-05-16
Primary completion
2024-03-21
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Ulotaront

Sponsors

Sumitomo Pharmaceuticals AmericaLead Sponsor

Sites

51 total
Konan-shi, JapanAkita, JapanHachinohe-shi, JapanChiba, JapanIchikawa-shi, JapanFukui-shi, JapanFukuoka, JapanFukuoka, JapanFukuoka, JapanFukuoka, JapanFukuoka, JapanOmuta-shi, Japan

Linked catalysts

1
A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 — primary completion2024-03-21

Facts & assertions

4 sourced
Enrollment
68
Phase
PHASE3
Primary Completion Date
2024-03-21
Status
TERMINATED
relationships
The graph out of here
drug
Ulotaront
drug
lead_sponsor
Sumitomo Pharmaceuticals America
company
indication
Schizophrenia
indication
Schizophrenia
indication